Morgan Stanley Checkpoint Therapeutics, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.02 - $10.6 $3,674 - $38,181	-3,602 Reduced 11.92%	26,620 $28,000
Q2 2022 Oct 27, 2022	SELL	$0.97 - $1.77 $7,960 - $14,526	-8,207 Reduced 21.36%	30,222 $32,000
Q2 2022 Aug 15, 2022	SELL	$0.97 - $1.77 $7,960 - $14,526	-8,207 Reduced 21.36%	30,222 $32,000
Q1 2022 Oct 27, 2022	BUY	$1.53 - $3.25 $12,556 - $26,672	8,207 Added 27.16%	38,429 $68,000
Q1 2022 May 13, 2022	SELL	$1.53 - $3.25 $34,562 - $73,417	-22,590 Reduced 37.02%	38,429 $68,000
Q4 2021 Feb 14, 2022	SELL	$2.68 - $4.46 $152,827 - $254,331	-57,025 Reduced 48.31%	61,019 $190,000
Q3 2021 Nov 15, 2021	BUY	$2.5 - $3.53 $295,110 - $416,695	118,044 New	118,044 $390,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $299M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.